COVID-19 Vaccination Alters NK Cell Dynamics and Transiently Reduces HBsAg Titers Among Patients With Chronic Hepatitis B
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Coronavirus disease 2019 (COVID-19) vaccination may non-specifically alter the host immune system. This study aimed to evaluate the effect of COVID-19 vaccination on hepatitis B surface Ag (HBsAg) titer and host immunity in chronic hepatitis B (CHB) patients. Consecutive 2,797 CHB patients who had serial HBsAg measurements during antiviral treatment were included in this study. Changes in the HBsAg levels after COVID-19 vaccination were analyzed. The dynamics of NK cells following COVID-19 vaccination were also examined using serial blood samples collected prospectively from 25 healthy volunteers. Vaccinated CHB patients (n=2,329) had significantly lower HBsAg levels 1–30 days post-vaccination compared to baseline (median, −21.4 IU/ml from baseline), but the levels reverted to baseline by 91–180 days (median, −3.8 IU/ml). The velocity of the HBsAg decline was transiently accelerated within 30 days after vaccination (median velocity: −0.06, −0.39, and −0.04 log10 IU/ml/year in pre-vaccination period, days 1–30, and days 31–90, respectively). In contrast, unvaccinated patients (n=468) had no change in HBsAg levels. Flow cytometric analysis showed that the frequency of NK cells expressing NKG2A, an NK inhibitory receptor, significantly decreased within 7 days after the first dose of COVID-19 vaccine (median, −13.1% from baseline; p<0.001). The decrease in the frequency of NKG2A+ NK cells was observed in the CD56dimCD16+ NK cell population regardless of type of COVID-19 vaccine. COVID-19 vaccination leads to a rapid, transient decline in HBsAg titer and a decrease in the frequency of NKG2A+ NK cells.
Abstract
Coronavirus disease 2019 (COVID-19) vaccination may non-specifically alter the host immune system. This study aimed to evaluate the effect of COVID-19 vaccination on hepatitis B surface Ag (HBsAg) titer and host immunity in chronic hepatitis B (CHB) patients. Consecutive 2,797 CHB patients who had serial HBsAg measurements during antiviral treatment were included in this study. Changes in the HBsAg levels after COVID-19 vaccination were analyzed. The dynamics of NK cells following COVID-19 vaccination were also examined using serial blood samples collected prospectively from 25 healthy volunteers. Vaccinated CHB patients (n=2,329) had significantly lower HBsAg levels 1–30 days post-vaccination compared to baseline (median, −21.4 IU/ml from baseline), but the levels reverted to baseline by 91–180 days (median, −3.8 IU/ml). The velocity of the HBsAg decline was transiently accelerated within 30 days after vaccination (median velocity: −0.06, −0.39, and −0.04 log10 IU/ml/year in pre-vaccination period, days 1–30, and days 31–90, respectively). In contrast, unvaccinated patients (n=468) had no change in HBsAg levels. Flow cytometric analysis showed that the frequency of NK cells expressing NKG2A, an NK inhibitory receptor, significantly decreased within 7 days after the first dose of COVID-19 vaccine (median, −13.1% from baseline; p<0.001). The decrease in the frequency of NKG2A+ NK cells was observed in the CD56dimCD16+ NK cell population regardless of type of COVID-19 vaccine. COVID-19 vaccination leads to a rapid, transient decline in HBsAg titer and a decrease in the frequency of NKG2A+ NK cells.
참고문헌 (40)
- Thomas DL, "Global elimination of chronic hepatitis", N Engl J Med, 380, pp.2041~2050 (2019)
- Shin EC, "Immune responses and immunopathology in acute and chronic viral hepatitis", Nat Rev Immunol, 16, pp.509~523 (2016)
- Tout I, "Hepatitis B surface antigen seroclearance : immune mechanisms, clinical impact, importance for drug development", J Hepatol, 73, pp.409~422 (2020)
- Yip TC, "HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues", J Hepatol, 70, pp.361~370 (2019)
- Dagan N, "BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting", N Engl J Med, 384, pp.1412~1423 (2021)
- Altmann DM, "COVID-19 vaccination : the road ahead", Science, 375, pp.1127~1132 (2022)
- Moss P, "The T cell immune response against SARS-CoV-2", Nat Immunol, 23, pp.186~193 (2022)
- Osawa Y, "Cases of rapid hepatitis B surface antigen reduction after COVID-19 vaccination", Intern Med, 62, pp.51~57 (2023)
- Boettler T, "SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis", J Hepatol, 77, pp.653~659 (2022)
- Hasegawa N, "Autoimmune hepatitis with history of HCV treatment triggered by COVID-19 vaccination : case report and literature review", Clin J Gastroenterol, 15, pp.791~795 (2022)
- Efe C, "Liver injury after SARS-CoV-2 vaccination : features of immune-mediated hepatitis, role of corticosteroid therapy and outcome", Hepatology, 76, pp.1576~1586 (2022)
- Lensen R, "Hepatitis C virus reactivation following COVID-19 vaccination-a case report", Int Med Case Rep J, 14, pp.573~576 (2021)
- Hu CY, "Hepatitis B virus infection flare induced acute-on-chronic liver failure after COVID-19 vaccination : a case report", Hepat Mon, 21, pp.e126460~ (2021)
- Chung GE, "Correlation between results of semi-quantitative and quantitative tests for hepatitis B virus surface antigen among patients achieving viral suppression with antiviral treatment", Diagnostics(Basel), 12, pp.1757~ (2022)
- Kim H, "Molecular epidemiology of hepatitis B virus(HBV)genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
- "Coronavirus (COVID-19), Republic of Korea"[URL]
- "COVID-19 antibody positivity survey results and plans (press release)"[URL]
- Seto WK, "Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment", J Gastroenterol Hepatol, 29, pp.1028~1034 (2014)
- Chen CH, "Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy", Hepatol Int, 14, pp.317~325 (2020)
- Fisicaro P, "Early kinetics of innate and adaptive immune responses during hepatitis B virus infection", Gut, 58, pp.974~982 (2009)
- Tong S, "Natural killer cell activation contributes to hepatitis B viral control in a mouse model", Sci Rep, 7, pp.314~ (2017)
- Moretta A, "Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis", Annu Rev Immunol, 19, pp.197~223 (2001)
- Vivier E, "Functions of natural killer cells", Nat Immunol, 9, pp.503~510 (2008)
- Cooper MA, "Human natural killer cells : a unique innate immunoregulatory role for the CD56bright subset", Blood, 97, pp.3146~3151 (2001)
- Li F, "Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice", Gastroenterology, 144, pp.392~401 (2013)
- Creelan BC, "The NKG2A immune checkpoint-a new direction in cancer immunotherapy", Nat Rev Clin Oncol, 16, pp.277~278 (2019)
- Rehermann B, "Natural killer cells in viral hepatitis", Cell Mol Gastroenterol Hepatol, 1, pp.578~588 (2015)
- Zhang C, "NKG2A is a NK cell exhaustion checkpoint for HCV persistence", Nat Commun, 10, pp.1507~ (2019)
- Azzolini E, "mRNA COVID-19 vaccine booster fosters B-and T-cell responses in immunocompromised patients", Life Sci Alliance, 5 (2022)
- Diniz MO, "NK cells limit therapeutic vaccine-induced CD8+T cell immunity in a PD-L1-dependent manner", Sci Transl Med, 14 (2022)
- La Sala L, "SARS-CoV-2 immunization orchestrates the amplification of IFNγ-producing T cell and NK cell persistence", Front Immunol, 13, pp.798813~ (2022)
- Ma Q, "Hepatitis B e antigen induces NKG2A+ natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection", Front Cell Dev Biol, 8, pp.421~ (2020)
- van Hall T, "Monalizumab : inhibiting the novel immune checkpoint NKG2A", J Immunother Cancer, 7, pp.263~ (2019)
- André P, "Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells", Cell, 175, pp.1731~1743 (2018)
- De Maria A, "Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-γ on activation", Proc Natl Acad Sci U S A, 108, pp.728~732 (2011)
- Guidotti LG, "Noncytolytic control of viral infections by the innate and adaptive immune response", Annu Rev Immunol, 19, pp.65~91 (2001)
- Zin Tun GS, "Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed", J Hepatol, 76, pp.747~749 (2022)
- Bril F, "Autoimmune hepatitis developing after coronavirus disease 2019(COVID-19)vaccine : one or even several swallows do not make a summer", J Hepatol, 75, pp.1256~1257 (2021)
- Rowley MW, "Immune reconstitution syndrome with initiation of treatment of HBV", HIV co-infection : activity flare associated with E antigen seroconversion, 2019, pp.18, 220~224
- Park KH, "Delayed NK cell reconstitution and reduced NK activity increased the risks of CMV disease in allogeneic-hematopoietic stem cell transplantation", Int J Mol Sci, 21, pp.3663~ (2020)